AIM:LID

Stock Analysis Report

Executive Summary

LiDCO Group Plc develops, manufactures, and sells hemodynamic monitoring equipment in the United Kingdom, the United States, Continental Europe, and internationally.


Snowflake Analysis

Flawless balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has LiDCO Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LID's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.0%

LID

2.3%

GB Medical Equipment

3.9%

GB Market


1 Year Return

85.3%

LID

-1.5%

GB Medical Equipment

-22.4%

GB Market

Return vs Industry: LID exceeded the UK Medical Equipment industry which returned -1.1% over the past year.

Return vs Market: LID exceeded the UK Market which returned -23% over the past year.


Shareholder returns

LIDIndustryMarket
7 Day10.0%2.3%3.9%
30 Day62.4%-15.6%-16.1%
90 Day65.5%-18.7%-26.1%
1 Year85.3%85.3%0.3%-1.5%-18.2%-22.4%
3 Year15.6%15.6%5.0%0.2%-11.7%-23.1%
5 Year-15.8%-15.8%35.9%24.4%1.9%-21.5%

Price Volatility Vs. Market

How volatile is LiDCO Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is LiDCO Group undervalued compared to its fair value and its price relative to the market?

3.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LID's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LID's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LID is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: LID is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LID's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LID is overvalued based on its PB Ratio (4x) compared to the GB Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is LiDCO Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

54.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LID is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LID is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LID is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LID's revenue (11.7% per year) is forecast to grow faster than the UK market (2.3% per year).

High Growth Revenue: LID's revenue (11.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LID's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has LiDCO Group performed over the past 5 years?

-61.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LID is currently unprofitable.

Growing Profit Margin: LID is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LID is unprofitable, and losses have increased over the past 5 years at a rate of -61.8% per year.

Accelerating Growth: Unable to compare LID's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LID is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-7.4%).


Return on Equity

High ROE: LID has a negative Return on Equity (-25.89%), as it is currently unprofitable.


Next Steps

Financial Health

How is LiDCO Group's financial position?


Financial Position Analysis

Short Term Liabilities: LID's short term assets (£4.4M) exceed its short term liabilities (£1.9M).

Long Term Liabilities: LID's short term assets (£4.4M) exceed its long term liabilities (£131.0K).


Debt to Equity History and Analysis

Debt Level: LID is debt free.

Reducing Debt: LID has not had any debt for past 5 years.


Balance Sheet

Inventory Level: LID has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if LID's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LID has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LID has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -32.7% each year


Next Steps

Dividend

What is LiDCO Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LID's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LID's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LID's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LID's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Matt Sassone

4.67s

Tenure

UK£262,000

Compensation

Mr. Matthew Sassone, also known as Matt, has been the Chief Executive Officer of LiDCO Group plc since August 14, 2015. Mr. Sassone served as Senior Vice President of Global Marketing at ArjoHuntleigh AB.  ...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD325.03K) is about average for companies of similar size in the UK market ($USD335.89K).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Matthew Sassone
CEO & Director4.67yrsUK£262.00k0.10% £21.3k
Terence O'Brien
Co-Founder & Member of Clinical Advisory Boardno datano data3.38% £703.4k
David Band
Co-Founder29.25yrsno datano data
Tim Hall
CFO, Company Secretary & Director1.08yrsno data0.041% £8.5k
Shane Doorish
Head of North America3.25yrsno datano data

4.7yrs

Average Tenure

Experienced Management: LID's management team is considered experienced (4.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Matthew Sassone
CEO & Director4.67yrsUK£262.00k0.10% £21.3k
Terence O'Brien
Co-Founder & Member of Clinical Advisory Boardno datano data3.38% £703.4k
Tim Hall
CFO, Company Secretary & Director1.08yrsno data0.041% £8.5k
Max Jonas
Member of Clinical Advisory Boardno datano datano data
Peter Grant
Non-Executive Chairman2.92yrsUK£45.00k0.39% £80.5k
Michael Pinsky
Member of Clinical Advisory Board14.5yrsno datano data
Philip Cooper
Non-Executive Director3.67yrsUK£30.00k1.09% £227.3k
James Wetrich
Non-Executive Director0.67yrno data0.0081% £1.7k

3.3yrs

Average Tenure

62yo

Average Age

Experienced Board: LID's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

LiDCO Group Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: LiDCO Group Plc
  • Ticker: LID
  • Exchange: AIM
  • Founded: 1991
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£20.816m
  • Shares outstanding: 244.17m
  • Website: https://www.lidco.com

Number of Employees


Location

  • LiDCO Group Plc
  • 16 Orsman Road
  • London
  • Greater London
  • N1 5QJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LIDAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJul 2001
LDGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2001
LDRU.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2001

Biography

LiDCO Group Plc develops, manufactures, and sells hemodynamic monitoring equipment in the United Kingdom, the United States, Continental Europe, and internationally. The company provides a range of closed and open pressure monitoring sets for use in the ICU, operating department, and Cath labs; and Stimpod NMS 450X, a quantitative neuromuscular blocking agent monitor. It also offers LiDCOunity, a hemodynamic monitor to support clinical decision making; and LiDCOrapid, a cardiac output monitor that analyses the blood pressure waveform to provide information in surgical and critically ill patients to help with fluid and drug management. In addition, the company offers LiDCOplus, a hemodynamic monitor, which provides assessment of the hemodynamic status of critical care and surgery patients; LiDCOview that offers clinical researchers and users with beat-to-beat hemodynamic data; and accessories, including blood pressure modules. LiDCO Group Plc was founded in 1991 and is headquartered in London, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 20:47
End of Day Share Price2020/04/01 00:00
Earnings2019/07/31
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.